Advertisement

Rivaroxaban Induced Thrombocytosis: A Perplexing Clinical Challenge

  • Arijit Nag
  • Maitreyyee Bhattacharyya
Correspondence

Notes

Funding

The authors haven’t received any external funding.

Compliance with Ethical Standards

Conflict of interest

The authors both declare that they have no conflict of interest.

Informed Consent

Informed consent was obtained from the patient.

References

  1. 1.
    CHMP Annex I Summary of Product Characteristics: Rivaroxaban. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf. Accessed 24 Nov 2017
  2. 2.
    Joyau C, Veyrac G, Piessard S, Delamarre-Damier F, Jolliet P (2014) P456: Rivaroxaban induced thrombocytosis: a not enough known adverse effect. Eur Geriatr Med 5:S225.  https://doi.org/10.1016/S1878-7649(14)70619-9 CrossRefGoogle Scholar

Copyright information

© Indian Society of Hematology and Blood Transfusion 2018

Authors and Affiliations

  1. 1.Institute of Hematology and Transfusion MedicineMedical College and Hospital, KolkataKolkataIndia

Personalised recommendations